NLS Pharmaceutics Ltd.
13F holders, Q1 2025 (March 31)2holders
0new positions
0sold out
$1.54avg. 13F price*
At the end of Q1 2025, 2 institutions reported holding NLS Pharmaceutics Ltd. in their 13F filings, unchanged from Q4 2024. 0 opened new positions and 0 sold out. The largest holders were BVF Inc. ($221K) and UBS Group AG ($40K).
- Company
- NLS Pharmaceutics Ltd.
- CUSIP
- H57830137
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q4 2024 → Q1 2025: 17,445 shares bought, net +17,445 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| BVF Inc. | 0.01% | No change | 143,676 | $221K |
| UBS Group AG | 0.00% | Add +210.4% | 25,737 | $40K |
"% of holder's portfolio" is NLS PHARMACEUTICS LTD's weight in each manager's 13F, not the share of NLS Pharmaceutics Ltd. the manager owns.